News | Embolic Protection Devices | April 20, 2018

Emboline Inc. Completes Funding for TAVR Embolic Protection Trial

Money will fund clinical trial for Emboliner Embolic Protection Catheter

Emboline Inc. Completes Funding for TAVR Embolic Protection Trial

April 20, 2018 — Emerging medical device company Emboline Inc. announced it has completed a Series B funding round totaling over $10 million for its total embolic protection device for transcatheter aortic valve replacement (TAVR) procedures. The funding includes $3 million in new equity financing from multiple investors led by SV Tech Ventures and Shangbay Capital, and over $7 million in conversion of previously-issued convertible notes.

"We have been closely monitoring the development of the Emboliner since 2015 and are encouraged by the potential this unique technology has to improve the safety of TAVR and other interventional procedures," said Peng Cheng, managing partner at SV Tech Ventures. "This is an exciting time for Emboline as they begin their clinical studies, and we look forward to continuing our work with the Emboline team to bring this technology to patients across the globe."

As part of the financing, ShangBay Capital's William Dai will join Cheng on the Emboline board of directors.

The working capital will be used to fund the SafePass Clinical trial for the Emboliner Embolic Protection Catheter, the subsequent European CE Mark submission and initial commercial launch.

"The risks of stroke and other neurological damage from TAVR have been getting increased attention in the cardiology community. We recognize that managing these risks will be critical to expanding TAVR into lower-risk patient populations," said William Dai, founding partner at ShangBay Capital.

The Emboliner is a next-generation approach to reducing the risk of cerebral embolic events or stroke that patients may face following TAVR procedures. The device’s design presents significant improvements on first-generation solutions by offering the following:

  • More effective coverage of all cerebral branches with fewer anatomical limitations;
  • Full-body embolic protection, capturing both cerebral and non-cerebral debris;
  • No additional procedural access required;
  • Minimal interference with devices necessary to complete the procedure; and
  • Outstanding ease-of-use and device control

For more information: www.emboline.com

 

Related Content

TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th
Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols, but the CHOWNOW study found patients do not need to fast and will have similar outcomes. #SCAI2020
Feature | Cath Lab | May 18, 2020
May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, o
htisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiography and Interventions (SCAI) and chief, Division of Cardiovascular Medicine at UC San Diego Medical Center,
Podcast | Cath Lab | May 13, 2020
This podcast is an interview with Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiograp
Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.
Videos | Cath Lab | January 09, 2020
Haval Chweich, M.D., medical director of the cardiac critical care unit (CCU) at Tufts Medical Center, and assistant...
People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.  In early December 2019, leaders of the European Association for Cardiothoracic Surgery (EACTS) withdrew their support for European practice guidelines that endorse the use of coronary stents in many patients with left main coronary artery disease.

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.

News | Cath Lab | January 02, 2020 | Dave Fornell, Editor
January 2, 2020 — In early December 2019, leaders of the European As...